A Phase 1B Study of Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer
Phase of Trial: Phase I/II
Latest Information Update: 16 Aug 2016
At a glance
- Drugs Donafenib (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 12 Aug 2016 Planned End Date changed from 1 Aug 2016 to 1 Aug 2017.
- 12 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
- 12 Aug 2016 Status changed from active, no longer recruiting to recruiting.